Company Focus
Icon
Latest Icon News
Pharmaceutical
As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field. 13 September 2024
Related News
Insights
Company Spotlight
A biopharma company dedicated to advancing innovative therapies for neurological and psychiatric disorders.
Latest News & Features of interest to Icon
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Biosimilars
The US Food and Drug Administration approved 50 novel drugs in 2024, continuing to outpace its global regulatory peers. 10 January 2025
Biotechnology
European biotech start-ups Numab Therapeutics and AnaCardio have raised new funding to advance their pipelines, adding positive momentum to the sector at the start of the new year. 10 January 2025
Biotechnology
USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China. 10 January 2025
Biotechnology
German family-owned pharma major Boehringer Ingelheim has licensed antibody-drug conjugates ADC technology from Netherlands-based Synaffix, a Lonza company. 9 January 2025
Biotechnology
Shares in French food allergy biotech DBV Technologies looked set to close more than 10% higher on Thursday. 9 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Biotechnology
Sanofi has announced promising results from its Phase III IRAKLIA study, which tested a subcutaneous version of Sarclisa (isatuximab) in combination with chemo, in multiple myeloma. 9 January 2025
Biotechnology
Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research collaboration and option to license agreement (RCO) with Japan’s Chugai Pharmaceutical. 9 January 2025
Biotechnology
UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from resilient individuals, has entered a collaboration with US pharma major Eli Lilly to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS). 9 January 2025
Latest In Brief for Icon
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix, GSK’s recombinant zoster vaccine for the prevention of shingles (herpes zoster). 10 January 2025
Latest Relevant Ones To Watch News
Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major Biogen has made a nonbinding proposal to acquire all of the outstanding shares of Sage not already owned by Biogen for $7.22 per share. 11 January 2025
10 January 2025
8 January 2025
6 January 2025
3 January 2025
2 January 2025
27 December 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze